Safety and efficacy preliminary analysis of first-line systemic therapy with atezolizumab plus bevacizumab in Spanish patients with unresectable hepatocellular carcinoma not previously treated with systemic therapy: phase IIIb ATHECA trial

被引：0

作者：

Reig, Maria ^{[1
]}

Luque, Natalia ^{[2
]}

Lledo, Jose Luis ^{[3
]}

Matilla, Ana ^{[4
]}

Montero, Jose Luis ^{[5
]}

Pazo-Cid, Roberto ^{[6
]}

Varela, Maria ^{[7
]}

Borras, Mar ^{[8
]}

Ordonez, Jose-Manuel ^{[8
]}

Argemi, Josep Maria ^{[9
]}

Bruix, Jordi ^{[1
]}

Gomez-Martin, Carlos ^{[10
]}

Perez-Lopez, Raquel ^{[11
]}

Rimola, Jordi ^{[12
]}

Sangro, Bruno ^{[13
]}

Sastre, Javier ^{[14
]}

机构：

[1] Hosp Clin Barcelona, BCLC Grp, Liver Unit, IDIBAPs, Barcelona, Spain

[2] Hosp Univ Jaen, Jaen, Spain

[3] Univ Alcala, Gastroenterol & Hepatol Serv, IRYCIS, CIBEREHD,Hosp Univ Ramon y Cajal, Madrid, Spain

[4] Hosp Gen Univ Gregorio Maranon, Digest Serv, CIBEREHD, Madrid, Spain

[5] Hosp Univ Reina Sofia, Liver Unit, Cordoba, Spain

[6] Hosp Univ Miguel Servet, Dept Med Oncol, Zaragoza, Spain

[7] Univ Oviedo, Dept Gastroenterol, Liver Unit, IUOPA,ISPA,FINBA,Hosp Univ Cent Asturias, Oviedo, Spain

[8] Roche Farma SA, Dept Med, Madrid, Spain

[9] Univ Navarra Clin, Liver Unit, Pamplona, Spain

[10] Univ Hosp Octubre, Med Oncol, Madrid, Spain

[11] Vall dHebron Inst Oncol Cellex Ctr, Radi Grp, Barcelona, Spain

[12] Hosp Clin Barcelona, Radiol Dept, BCLC Grp, IDIBAPs, Barcelona, Spain

[13] Univ Navarra Clin, Liver Unit, CIBEREHD, Madrid, Spain

[14] Hosp Clin Univ San Carlos, Med Oncol, Madrid, Spain

来源：

JOURNAL OF HEPATOLOGY | 2024年 / 80卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

THU-501

引用

页码：S455 / S456

页数：2

共 50 条

[1] Safety interim analyses of first-line systemic therapy with atezolizumab plus bevacizumab (ATZ plus BEV) in patients from Spain with unresectable hepatocellular carcinoma (HCC): Phase IIIb ATHECA
Monzon, M. E. Reig
Caro, N. Luque
Bruix, J.
Martin, C. Gomez
Sangro, B.
Varela, J. Sastre
Tres, J. M. Ordonez
Argemi, J.
Lopez, R. Perez
Candela, M. P. Torres
Lledo-Navarro, J. L.
Pena, A. M. Matilla
Montero, J-L.
Cid, R. A. Pazo
Varela, M.
ANNALS OF ONCOLOGY, 2023, 34 : S606 - S607
[2] Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
Tada, Toshifumi
Kumada, Takashi
Hiraoka, Atsushi
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
Nishimura, Takashi
Hatanaka, Takeshi
Kakizaki, Satoru
Shimada, Noritomo
Kawata, Kazuhito
Tada, Fujimasa
Ohama, Hideko
Nouso, Kazuhiro
Morishita, Asahiro
Tsutsui, Akemi
Nagano, Takuya
Itokawa, Norio
Okubo, Tomomi
Arai, Taeang
Imai, Michitaka
Kosaka, Hisashi
Naganuma, Atsushi
Matono, Tomomitsu
Koizumi, Yohei
Nakamura, Shinichiro
Kaibori, Masaki
Iijima, Hiroko
Hiasa, Yoichi
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 (08) : 1389 - 1397
[3] Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Niizeki, Takashi
Tokunaga, Takayuki
Takami, Yuko
Wada, Yoshiyuki
Harada, Masaru
Shibata, Michihiko
Nakao, Kazuhiko
Sasaki, Ryu
Hirai, Fumihito
Shakado, Satoshi
Yoshizumi, Tomoharu
Itoh, Shinji
Yatsuhashi, Hiroshi
Bekki, Shigemune
Ido, Akio
Mawatari, Seiichi
Honda, Koichi
Sugimoto, Rie
Senju, Takeshi
Takahashi, Hirokazu
Kuwashiro, Takuya
Maeshiro, Tatsuji
Nakamuta, Makoto
Aratake, Yoshifusa
Yamashita, Tsutomu
Otsuka, Yuichiro
Matsumoto, Shuichi
Sohda, Tetsuro
Shimose, Shigeo
Murotani, Kenta
Tanaka, Yasuhito
TARGETED ONCOLOGY, 2022, 17 (06) : 643 - 653
[4] Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Takashi Niizeki
Takayuki Tokunaga
Yuko Takami
Yoshiyuki Wada
Masaru Harada
Michihiko Shibata
Kazuhiko Nakao
Ryu Sasaki
Fumihito Hirai
Satoshi Shakado
Tomoharu Yoshizumi
Shinji Itoh
Hiroshi Yatsuhashi
Shigemune Bekki
Akio Ido
Seiichi Mawatari
Koichi Honda
Rie Sugimoto
Takeshi Senju
Hirokazu Takahashi
Takuya Kuwashiro
Tatsuji Maeshiro
Makoto Nakamuta
Yoshifusa Aratake
Tsutomu Yamashita
Yuichiro Otsuka
Shuichi Matsumoto
Tetsuro Sohda
Shigeo Shimose
Kenta Murotani
Yasuhito Tanaka
Targeted Oncology, 2022, 17 : 643 - 653
[5] Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial
Piscaglia, F.
Masi, G.
Martinelli, E.
Cabibbo, G.
Di Maio, M.
Gasbarrini, A.
Iavarone, M.
Antonuzzo, L.
Mazzaferro, V.
Ballestrero, A.
Garufi, C.
Bergamo, F.
Celsa, C.
Marino, D.
Tovoli, F.
Ponziani, F. R.
Pressiani, T.
Astolfi, C.
Gazzoli, G. C.
Ciardiello, F.
Daniele, B.
Rimassa, L.
ESMO OPEN, 2025, 10 (02)
[6] COMPARISON EFFICACY AND SAFETY BETWEEN ATEZOLIZUMAB PLUS BEVACIZUMAB AND LENVATINIB AS FIRST-LINE SYSTEMIC THERAPY FOR HEPATOCELLULAR CARCINOMA: A REAL-WORLD STUDY
Boonkaya, Sangdao
Thanapirom, Kessarin
Siripon, Nipaporn
Thaimai, Panarat
Ananchuensook, Prooksa
Sriphoosanaphan, Supachaya
Tanasanvimon, Surbpong
Treeprasertsuk, Sombat
Komolmit, Piyawat
GASTROENTEROLOGY, 2024, 166 (05) : S73 - S74
[7] Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study
Storandt, Michael H.
Zemla, Tyler J.
Patell, Kanchi
Naleid, Nikolas
Gile, Jennifer J.
Tran, Nguyen H.
Chakrabarti, Sakti
Jin, Zhaohui
Borad, Mitesh
Mahipal, Amit
ONCOLOGIST, 2024, 29 (11): : 986 - 996
[8] Efficacy and tolerability of atezolizumab and bevacizumab in patients with hepatocellular carcinoma previously treated with systemic therapy: a global, observational study
Joerg, Vincent
Scheiner, Bernhard
D'Alessio, Antonio
Fulgenzi, Claudia
Schoenlein, Martin
Kocheise, Lorenz
Lohse, Ansgar W.
Huber, Samuel
Wege, Henning
Kaseb, Ahmed
Wang, Yinghong
Muzaffar, Mahvish
Abugabal, Yehia
Chamseddine, Shadi
Phen, Samuel
Cheon, Jaekyung
Lee, Pei-Chang
Balcar, Lorenz
Krall, Anja
Ang, Celina
Wu, Linda
Saeed, Anwaar
Huang, Yi-Hsiang
Bengsch, Bertram
Rimassa, Lorenza
Weinmann, Arndt
Stauber, Rudolf E.
Korolewicz, James
Pinter, Matthias
Singal, Amit
Chon, Hong Jae
Pinato, David J.
Schulze, Kornelius
von Felden, Johann
JOURNAL OF HEPATOLOGY, 2023, 78 : S582 - S582
[9] Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety
Shao, Yu-Yun
Feng, Yin-Hsun
Yen, Chia-Jui
Yang, Tsai-Sheng
Shen, Ying-Chun
Chao, Yee
Chen, Jen-Shi
Su, Ching-Yen
Chen, Wei-Jen
Hsiang, Hwa-Lin
Hsu, Chih-Hung
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2022, 121 (12) : 2430 - 2437
[10] Importance of Atezolizumab Plus Bevacizumab Combination Treatment as First-line Therapy for Immunological Changes in Patients With Unresectable Hepatocellular Carcinoma
Kobayashi, Kojiro
Nagai, Hidenari
Matsui, Teppei
Matsuda, Takahisa
Higai, Koji
ANTICANCER RESEARCH, 2023, 43 (10) : 4601 - 4609

← 1 2 3 4 5 →